Rogers Ba, Little Nj, Jones C
Trauma and Orthopaedics, St George's Hospital, London, UK.
Br J Hosp Med (Lond). 2009 Nov;70(11):630-3. doi: 10.12968/hmed.2009.70.11.45051.
Low molecular weight heparins have been used to reduce thromboembolic risk for at least 20 years, but their use is not without risk. This article considers the incidence, monitoring, treatment and lack of insight about heparin-induced thrombocytopenia - a potentially fatal complication of low molecular weight heparin use.
低分子量肝素已被用于降低血栓栓塞风险至少20年了,但其使用并非毫无风险。本文探讨了肝素诱导的血小板减少症的发生率、监测、治疗以及人们对它缺乏了解的情况——这是使用低分子量肝素可能导致的一种潜在致命并发症。